79 results
Page 2 of 4
8-K
EX-99.1
o0mhjbbl
19 Nov 21
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
7:08am
8-K
EX-99.1
jil0g
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
8-K
EX-99.1
kicl2roq9sm
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
EX-99.1
amtznqxpgsw2q5ql4abg
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm
8-K
EX-99.1
iexuzil6 duk6ur
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-2.1
lryq2qko
25 Nov 19
Alkermes Completes Acquisition of Rodin Therapeutics
5:26pm